Frontiers in Oncology | Cancer Immunity and Immunotherapy

Original Research

Published on 15 Jan 2024

Clear cell renal cell carcinoma: immunological significance of alternative splicing signatures

in Cancer Immunity and Immunotherapy

Jiayu Zhang
Hongyi Jiang
Dapang Rao
Xishi Jin

Frontiers in Oncology

doi 10.3389/fonc.2023.1206882

1,384 views
1 citation

Original Research

Published on 09 Jan 2024

Evaluating the predictive significance of systemic immune-inflammatory index and tumor markers in lung cancer patients with bone metastases

in Cancer Immunity and Immunotherapy

Jinxian He
Gaofeng Liang
Hongyan Yu
Chengbin Lin
Weiyu Shen

Frontiers in Oncology

doi 10.3389/fonc.2023.1338809

1,791 views
3 citations

Perspective

Published on 08 Jan 2024

Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine

in Cancer Immunity and Immunotherapy

Christine M. Minnar
Grace Lui
James L. Gulley
Jeffrey Schlom
Sofia R. Gameiro

Frontiers in Oncology

doi 10.3389/fonc.2023.1321318

5,244 views
10 citations

Review

Published on 04 Jan 2024

Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients

in Cancer Immunity and Immunotherapy

Iuliia Kovalenko
Wern Lynn Ng
Yimin Geng
Yinghong Wang
Pavlos Msaouel
Shailender Bhatia
Petros Grivas
Raed Benkhadra
Omar Alhalabi

Frontiers in Oncology

doi 10.3389/fonc.2023.1238517

2,574 views

Original Research

Published on 03 Jan 2024

T-cell receptor determinants of response to chemoradiation in locally-advanced HPV16-driven malignancies

in Cancer Immunity and Immunotherapy

Pablo Nenclares
Adrian Larkeryd
Floriana Manodoro
Jen Y. Lee
Susan Lalondrelle
Duncan C. Gilbert
Marco Punta
Ben O’Leary
Antonio Rullan
Anguraj Sadanandam

Frontiers in Oncology

doi 10.3389/fonc.2023.1296948

2,352 views
3 citations

Original Research

Published on 22 Dec 2023

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

in Cancer Immunity and Immunotherapy

Qin Wang
Chen Qi
Jing Luo
Nan Xu
Mao-tian Xu
Yong Qiang
Chi Zhang
Yi Shen

Frontiers in Oncology

doi 10.3389/fonc.2023.1239451

2,754 views
2 citations

Review

Published on 22 Dec 2023

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas

in Cancer Immunity and Immunotherapy

Zhaoxia Li
Wei Guo
Ou Bai

Frontiers in Oncology

doi 10.3389/fonc.2023.1301437

3,801 views
6 citations

Original Research

Published on 21 Dec 2023

Utilization of cancer immunotherapy in sub-Saharan Africa

in Cancer Immunity and Immunotherapy

Elizabeth Olatunji
Saloni Patel
Katy Graef
Adedayo Joseph
Nwamaka Lasebikan
Abba Mallum
Chinelo Chigbo
Elizabeth Jaffee
Wil Ngwa

Frontiers in Oncology

doi 10.3389/fonc.2023.1266514

2,912 views
2 citations

Original Research

Published on 21 Dec 2023

Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

in Cancer Immunity and Immunotherapy

Youlong Wang
Qi Huang
Guanqing Zhong
Jun Lv
Qinzhi Guo
Yifei Ma
Xinjia Wang
Jiling Zeng

Frontiers in Oncology

doi 10.3389/fonc.2023.1191611

1,877 views

Original Research

Published on 21 Dec 2023

Exploration of cancer associated fibroblasts phenotypes in the tumor microenvironment of classical and pleomorphic Invasive Lobular Carcinoma

in Cancer Immunity and Immunotherapy

Harsh Batra
Qingqing Ding
Renganayaki Pandurengan
Heladio Ibarguen
Neus Bota Rabassedas
Aysegul Sahin
Ignacio Wistuba
Edwin Roger Parra
Maria Gabriela Raso

Frontiers in Oncology

doi 10.3389/fonc.2023.1281650

2,484 views
3 citations

Review

Published on 20 Dec 2023

Review: therapeutic approaches for circadian modulation of the glioma microenvironment

in Cancer Immunity and Immunotherapy

Ella A. Nettnin
Thien Nguyen
Sophia Arana
Maria Isabel Barros Guinle
Cesar A. Garcia
Erin M. Gibson
Laura M. Prolo

Frontiers in Oncology

doi 10.3389/fonc.2023.1295030

2,925 views
2 citations

Case Report

Published on 15 Dec 2023

Long-term survival in a patient with primary refractory AML after salvage allogeneic hematopoietic transplantation and post-transplant localized irradiation and venetoclax maintenance: a case report

in Cancer Immunity and Immunotherapy

Yili Fan
Luyao Wang
Boxiao Chen
Jiawei Zhang
Luyu Yang
Xi Qiu
Huawei Jiang
Lei Zhu
Chao Wang
Yang Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1329858

1,459 views

Original Research

Published on 13 Dec 2023

Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery

in Cancer Immunity and Immunotherapy

Xudan Wang
Weiwei Cao
Yan Qiu
Hongchen Ji
Juzheng Yuan
Weikang Wu
Fuyuan Liu
Liangyong Feng
Rui Ding
Xiao Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1174999

1,678 views
2 citations

Correction

Published on 13 Dec 2023

Corrigendum: Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

in Cancer Immunity and Immunotherapy

Shuqi Xie
Mengchao Wang
Chuanxiu Zeng
Yan Ou
Lu Zhao
Dong Wang
Liwei Chen
Fanming Kong
Dan Yi

Frontiers in Oncology

doi 10.3389/fonc.2023.1338060

772 views

Original Research

Published on 12 Dec 2023

Deciphering the Hypoxia-immune interface in esophageal squamous carcinoma: a prognostic network model

in Cancer Immunity and Immunotherapy

Jie Hu
Qilong Liu
Bi Feng
Yanling Lu
Kai Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1296814

1,351 views

Systematic Review

Published on 07 Dec 2023

Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

in Cancer Immunity and Immunotherapy

Lu Ye
Fei Zhou
Dongdong Cheng
Ming Xie
Xiaoli Yan
Yuyu Xue
Qian Yang
Rong Jia
Lili Zhong
Li Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1240318

4,375 views
3 citations

Navigation group

Articles

Clear cell renal cell carcinoma: immunological significance of alternative splicing signatures

Evaluating the predictive significance of systemic immune-inflammatory index and tumor markers in lung cancer patients with bone metastases

Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine

Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients

T-cell receptor determinants of response to chemoradiation in locally-advanced HPV16-driven malignancies

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas

Utilization of cancer immunotherapy in sub-Saharan Africa

Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

Exploration of cancer associated fibroblasts phenotypes in the tumor microenvironment of classical and pleomorphic Invasive Lobular Carcinoma

Review: therapeutic approaches for circadian modulation of the glioma microenvironment

Long-term survival in a patient with primary refractory AML after salvage allogeneic hematopoietic transplantation and post-transplant localized irradiation and venetoclax maintenance: a case report

Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery

Corrigendum: Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

Deciphering the Hypoxia-immune interface in esophageal squamous carcinoma: a prognostic network model

Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials